Forecast Of The Day: Roche’s Neuroscience Drugs Revenue

October 6th, 2021 by Trefis Team
-5.94%
Downside
39.56
Market
37.21
Trefis
RHHBY: Roche Holding logo
RHHBY
Roche Holding

What?

Roche Holding’s (OTC:RHHBY) Neuroscience Drugs Revenue rose from around $4.6 billion in 2019 to $5.5 billion in 2020. Trefis expects the metric to rise to almost $7 billion in 2021 and $7.4 billion in 2022.

Why?

Relevant Articles
  1. Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
  2. Will Roche Stock Rebound To Its 2022 Highs of $50?
  3. Is Roche Stock Undervalued At $33?
  4. What’s Driving Roche Stock?
  5. Company Of The Day: Roche Holdings
  6. What’s Happening With Roche (RHHBY) Stock?

Sales are being driven primarily by Ocrevus, a drug that is used to treat multiple sclerosis. Ocrevus has been one of Roche’s most successful launches, given the large size of the market for multiple sclerosis treatments.

So What?

We think the projected growth for Roche’s isn’t priced into the stock yet. We value Roche’s ADR at about $54 per share, a 13% premium over the current market price.

See Our Complete Analysis For Roche Holding’s

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates